Condition: Multiple Myeloma · Sponsor: AbbVie
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed. Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide. In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side eff…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| Beverly Hills Cancer Center /ID# 266921 | Beverly Hills, California, United States | Recruiting |
| Colorado Blood Cancer Institute /ID# 273751 | Denver, Colorado, United States | Recruiting |
| Washington University /ID# 266972 | St Louis, Missouri, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey /ID# 266833 | New Brunswick, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282 | New York, New York, United States | Recruiting |
| University Of North Carolina Health Care - Hillsborough Campus /ID# 278230 | Hillsborough, North Carolina, United States | Recruiting |
| Swedish Medical Center - Seattle /ID# 268052 | Seattle, Washington, United States | Recruiting |
| Blacktown Hospital /ID# 265983 | Blacktown, New South Wales, Australia | Recruiting |
| Wollongong Hospital /ID# 265625 | Wollongong, New South Wales, Australia | Recruiting |
| The Alfred Hospital /ID# 265981 | Melbourne, Victoria, Australia | Recruiting |
| Austin Hospital /ID# 265984 | Melbourne, Victoria, Australia | Recruiting |
| Sir Charles Gairdner Hospital /ID# 265985 | Nedlands, Western Australia, Australia | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06896916